Invitrogen

CD135 (Flt3) Monoclonal Antibody (BV10A4H2), APC, eBioscience™

CD135 (Flt3) Antibody in Flow Cytometry (Flow)

图: 1 / 1

CD135 (Flt3) Antibody (17-1357-42) in Flow

Staining of REH cell line with Mouse IgG1 kappa Isotype Control APC (Product # 17-4714-81) (blue histogram) or Anti-Human CD135 (Flt3) APC (purple histogram). Total viable cells were used for analysis.

Product Image Gallery

产品信息

17-1357-42

应用

建议稀释比

已发表文章

流式细胞分析 (Flow)

5 µL (0.5 µg)/test

查看4篇已发表文章 4篇已发表文章

产品规格

种属反应

Human

已发表种属

Human

宿主/亚型

Mouse / IgG1

分类

Monoclonal

类型

Antibody

克隆号

BV10A4H2

抗原

BV-173 leukemic cell line

查看免疫原

偶联物

APC APC APC

激发/发射光谱

651/660 nm 查看光谱

形式

Liquid

浓度

5 µL/Test

纯化类型

Affinity chromatography

保存液

PBS, pH 7.2, with 0.2% BSA

内含物

0.09% sodium azide

保存条件

4° C, store in dark, DO NOT FREEZE!

运输条件

Ambient (domestic); Wet ice (international)

AB_10609212

产品详细信息

Description: The BV10A4H2 monoclonal antibody reacts with human CD135, also known as Flk2/Flt3. A member of the tyrosine kinase receptor family, this 135-150 kDa molecule is expressed by multipotential progenitor cells including primitive B cell and myelomonocytic progenitors in fetal liver and adult bone marrow.

Applications Reported: The BV10A4H2 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This BV10A4H2 antibody has been pre-titrated and tested by flow cytometric analysis of REH cell line. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser.

Filtration: 0.2 µm post-manufacturing filtered.

靶标信息

FLT3 is a tyrosine protein kinase that is a member of the growth factor receptor tyrosine kinase family. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

How to use the Panel Builder

Watch the video to learn how to use the Invitrogen Flow Cytometry Panel Builder to build your next flow cytometry panel in 5 easy steps.

Product References

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.

Oncotarget

Tsuzuki H,Kawase T,Nakazawa T,Mori M,Yoshida T

17-1357-42 was used in Flow cytometry/Cell sorting to provide supportive evidence that the triple combination of ASP1235, venetoclax and azacitidine would improve the clinical outcome of ASP1235 monotherapy and venetoclax plus azacitidine regimen in AML patients.

Tue Dec 20 00:00:00 UTC 2022

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway.

Translational oncology

Nogami A,Okada K,Ishida S,Akiyama H,Umezawa Y,Miura O

17-1357-42 was used in Flow Cytometry to suggest that FLT3-ITD confers a resistance to the proteasome inhibitors on AML cells by protecting the mTORC1/Mcl-1 pathway through the STAT5/Pim axis, and inhibition of these signaling events remarkably enhances the therapeutic efficacy.

Fri Feb 01 00:00:00 UTC 2019

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

The Journal of experimental medicine

Mitchell K,Barreyro L,Todorova TI,Taylor SJ,Antony-Debré I,Narayanagari SR,Carvajal LA,Leite J,Piperdi Z,Pendurti G,Mantzaris I,Paietta E,Verma A,Gritsman K,Steidl U

17-1357 was used in Flow cytometry/Cell sorting to show that targeting of interleukin-1 receptor accessory protein via RNA interference, genetic deletion, or antibodies inhibits acute myeloid leukaemia pathogenesis in vitro and in vivo.

Mon Jun 04 00:00:00 UTC 2018

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Blood

Adamia S,Bar-Natan M,Haibe-Kains B,Pilarski PM,Bach C,Pevzner S,Calimeri T,Avet-Loiseau H,Lode L,Verselis S,Fox EA,Galinsky I,Mathews S,Dagogo-Jack I,Wadleigh M,Steensma DP,Motyckova G,Deangelo DJ,Quackenbush J,Tenen DG,Stone RM,Griffin JD

17-1357 was used in Flow cytometry/Cell sorting to suggest that NOTCH2 and FLT3 mis-splicing is a common characteristic of AML and has the potential to generate transcripts encoding proteins with altered function.

Thu May 01 00:00:00 UTC 2014

生物信息学

蛋白别名: CD135; CD135 antigen; fetal liver kinase 2; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLT-3; Fms-like tyrosine kinase 3; fms-related tyrosine kinase 3; growth factor receptor tyrosine kinase type III; OTTHUMP00000214829; Receptor-type tyrosine-protein kinase FLT3; RP11-153M24.3; Stem cell tyrosine kinase 1; STK-1

查看更多收起

基因别名: CD135; FLK-2; FLK2; FLT3; STK1

查看更多收起

UniProt ID: (Human) P36888

查看更多收起

Entrez Gene ID: (Human) 2322

查看更多收起

功能

transmembrane receptor protein tyrosine kinase activity cytokine receptor activity vascular endothelial growth factor-activated receptor activity protein binding ATP binding protein complex binding glucocorticoid receptor binding protein homodimerization activity transmembrane signal receptor

参与通路